Atypical hemolytic-uremic syndrome: A case report and literature review

American Journal of Case Reports

Volumn 16, Issue , 2015, Pages 110-114

  Rafiq, Arsalan ^a   Tariq, Hassan ^a   Abbas, Naeem ^a   Shenoy, Roopalekha ^a  

^a BRONX LEBANON HOSPITAL CENTER   (United States)

Author keywords

ADAM proteins; Hemolytic uremic syndrome; Purpura, thrombotic thrombocytopenic; Thrombotic microangiopathies

Indexed keywords

ANTIHYPERTENSIVE AGENT; COCAINE; CREATININE; ECULIZUMAB; GLYCERYL TRINITRATE; HAPTOGLOBIN; HYDRALAZINE; ISOSORBIDE MONONITRATE; LACTATE DEHYDROGENASE; METHADONE; METRONIDAZOLE; NIFEDIPINE; OPIATE; UREA; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE KIDNEY FAILURE; ADULT; ALERTNESS; ARTICLE; BLOOD PRESSURE REGULATION; BRAIN DISEASE; CASE REPORT; CLINICAL EXAMINATION; CLOSTRIDIUM DIFFICILE INFECTION; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DELIRIUM; FEMALE; FOLLOW UP; HEADACHE; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; LACUNAR STROKE; LIMB WEAKNESS; MALIGNANT HYPERTENSION; MIDDLE AGED; NEUROLOGIC EXAMINATION; PLASMAPHERESIS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT REFUSAL; ULTRASOUND; UREA NITROGEN BLOOD LEVEL; URINALYSIS; ALGORITHM; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLICATION; DIFFERENTIAL DIAGNOSIS; PROGNOSIS;

ALGORITHMS; ATYPICAL HEMOLYTIC UREMIC SYNDROME; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS;

EID: 84923825067     PISSN: None     EISSN: 19415923     Source Type: Journal    
DOI: 10.12659/AJCR.892907     Document Type: Article

References (36)

1. Nester CM, Thomas CP: Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology Am Soc Hematol Educ Program, 2012; 2012: 617–25.
2. Moake JL: Thrombotic microangiopathies. N Engl J Med, 2002; 347(8): 589–600.
3. Zheng XL1, Kaufman RM, Goodnough LT, Sadler JE: Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood, 2004; 103(11): 4043–9.
4. Kremer Hovinga JA, Vesely SK, Terrell DR et al: Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2010; 115 (8): 1500–11; quiz 1662.
5. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA et al: Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol, 2007; 18(8): 2392–400.
6. Proesmans, W: Typical and atypical hemolytic uremic syndrome. Kidney Blood Press Res, 1996; 19(3–4): 205–8.
7. Noris M, Remuzzi G: Atypical hemolytic-uremic syndrome. N Engl J Med, 2009; 361(17): 1676–87.
8. Cataland SR, Wu HM: Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies. Eur J Intern Med, 2013; 24(6): 486–91.
9. Sawai T, Nangaku M, Ashida A et al: Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Clin Exp Nephrol, 2014; 18(1): 4–9.
10. Warwicker P, Goodship TH, Donne RL et al: Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int, 1998; 53(4): 836–44.
11. Richards A, Buddles MR, Donne RL et al: Factor H mutations in hemolytic uremic syndrome cluster in exons 18–20, a domain important for host cell recognition. Am J Hum Genet, 2001; 68(2): 485–90.
12. Goodship TH, Liszewski MK, Kemp EJ et al: Mutations in CD46, a complement regulatory protein, predispose to atypical HUS. Trends Mol Med, 2004; 10(5): 226–31.
13. Richards A, Kemp EJ, Liszewski MK et al: Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci USA, 2003; 100(22): 12966–71.
14. Kavanagh D, Kemp EJ, Mayland E et al: Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol, 2005; 16(7): 2150–15.
15. Caprioli J, Noris M, Brioschi S et al: Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood, 2006; 108(4): 1267–79.
16. Moore I, Strain L, Pappworth I et al: Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood, 2010; 115(2): 379–87.
17. Zipfel PF, Edey M, Heinen S et al: Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet, 2007; 3(3): e41.
18. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J et al: Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA, 2007; 104(1): 240–45.
19. Delvaeye M, Noris M, De Vriese A et al: Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med, 2009; 361(4): 345–57.
20. Laurence J: Diagnosis of atypical hemolytic uremic syndrome: a review of case studies. Clin Adv Hematol Oncol, 2012; 10(10 Suppl.17): 9–11.
21. Sallée M, Daniel L, Piercecchi MD et al: Myocardial infarction is a complication of factor H-associated atypical HUS. Nephrol Dial Transplant, 2010; 25(6): 2028–32.
22. Zuber J, Le Quintrec M, Sberro-Soussan R et al: New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol, 2011; 7(1): 23–35.
23. Gordon LI, Kwaan HC: Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient. Semin Thromb Hemost, 1999; 25(2): 217–21.
24. Neild GH: Haemolytic-uraemic syndrome in practice. Lancet, 1994; 343(8894): 398–401.
25. Noris, M, Remuzzi G: Hemolytic uremic syndrome. J Am Soc Nephrol, 2005; 16(4): 1035–50.
26. Zuber J, Fakhouri F, Roumenina LT et al: Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol, 2012; 8(11): 643–57.
27. Nickavar A, Sotoudeh K: Assesment, treatment and prevention of atypical hemolytic uremic syndrome. Int J Prev Med, 2013; 4(1): 6–14.
28. Waters AM, Licht C: aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol, 2011; 26(1): 41–57.
29. Cho HY, Lee BS, Moon KC et al: Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate. Pediatr Nephrol, 2007; 22(6): 874–80.
30. Gruppo RA, Rother RP: Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med, 2009; 360(5): 544–46.
31. Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V et al: Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol, 2009; 4(8): 1312–16.
32. Rosales A, Riedl M, Zimmerhackl LB: Thrombotic microangiopathy: atypical HUS: current diagnostic and therapeutic approaches. Nat Rev Nephrol, 2010; 6(9): 504–6.
33. Ohanian M, Cable C, Halka K: Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol, 2011; 3: 5–12.
34. Prescott HC, Wu HM, Cataland SR, Baiocchi RA et al: Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome. Am J Hematol, 2010; 85(12): 976–77.
35. Vaisbich MH, Henriques Ldos S, Watanabe A et al: [Eculizumab for the treatment of atypical hemolytic uremic syndrome: case report and revision of the literature.] J Bras Nefrol, 2013; 35(3): 237–41 [in Portuguese].
36. Sana G, Dragon-Durey MA, Charbit M et al: Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol, 2014; 29(1): 75–83.